MedTrace Logo

Confirm the Effectiveness of Predictix Genetics Antidepressant -Guided Treatment in Adults With MDD

NCT05137197 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 354

Last updated 2021-11-30

No results posted yet for this study

Summary

A randomized, controlled, prospective, multicenter, patient and rater blinded study with 2 arms: Treatment as Usual (TAU) and Predictix Guided Treatment (PGT). The study will compare the rate of treatment response and remission among both groups; TAU vs PGT.

Conditions

Interventions

DEVICE

Predictix Genetics Antidepressant

Predictix Genetics Antidepressant (PGA) is a software tool that is intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with MDD.

Sponsors & Collaborators

  • Taliaz Ltd.

    lead INDUSTRY

Principal Investigators

  • Daniel Souery, MD · Psy Pluriel

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-04
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • Belgium
  • France
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05137197 on ClinicalTrials.gov